L3VLUP
ProSign in

PTGX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PTGXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PTGX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterPTGXJNJ
Q3 20201 holders, $54m30 holders, $26.2bn
Q4 20202 holders, $60m32 holders, $26.6bn
Q1 20212 holders, $87m31 holders, $25.3bn
Q2 20212 holders, $156m37 holders, $25.6bn
Q3 20214 holders, $130m40 holders, $24.1bn
Q4 20214 holders, $169m33 holders, $25.2bn
Q1 20223 holders, $110m35 holders, $28.2bn
Q2 20225 holders, $67m33 holders, $26.9bn
Q3 20223 holders, $53m36 holders, $25.4bn
Q4 20225 holders, $52m35 holders, $27.6bn
Q1 20234 holders, $116m42 holders, $24.5bn
Q2 20235 holders, $171m38 holders, $25.0bn
Q3 20232 holders, $109m37 holders, $18.9bn
Q4 20232 holders, $191m31 holders, $19.0bn
Q1 20245 holders, $248m32 holders, $19.7bn
Q2 20243 holders, $262m35 holders, $20.4bn
Q3 20243 holders, $286m28 holders, $22.3bn
Q4 20244 holders, $253m37 holders, $20.4bn
Q1 20254 holders, $354m32 holders, $20.5bn
Q2 20255 holders, $425m31 holders, $18.4bn
Q3 20258 holders, $790m32 holders, $23.7bn
Q4 202510 holders, $1.3bn29 holders, $27.8bn
Q1 20269 holders, $1.8bn34 holders, $35.6bn
Q2 20267 holders, $1.9bn33 holders, $39.1bn
PTGX

Protagonist Therapeutics Inc

Holders
10
Reported value
$1.3bn
Buyers
14
Sellers
14

Breadth 0 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PTGX (5)

Farallon Capital Management LLC, Holocene Advisors LP, Polen Capital Management LLC, Soros Fund Management LLC, Winton Group Ltd

Only JNJ (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →